Approach to medical allergy in terms of pathogenesis of different pathological conditions

I.R. Mavlyanov, A.Kh. Ashirmetov, Z.I. Mavlyanov
Keywords: medicinal allergy, immune system, genetic polymorphism.
Medicinskij al'manah, 2017, issue 3, pages 210-213.

In modern medicine huge interest causes the analysis of the nature of allergic diseases from positions of

a complete organism. Expression of «a civilization illness» which designates proliferation of such diseases

as cardiovascular pathologies, a cancer, various allergies, etc. was created. All these facts testify that

systems of protection of a human body against pathogens develop, answering change of living conditions

with formation of new elements of compensatory protection. These facts are confirmed by broad development

of allergic reactions which increased in mass scales. For example, in developing of a medicinal

allergy unreasonable application at the same time of several preparations (polipragmaziya) in treatment of

not serious illness and uncontrolled drug intake (self-treatment) is of great importance. Significant growth

in allergic diseases worldwide, their serious consequences determine need of knowledge by the doctor of

any specialty of the main theoretical and practical aspects of an allergy, ability to give emergency aid at

allergic states. Are given total approach to an assessment of pathogenesis of an allergic disease which

gives the chance to understand a number of situations which can be observed in the field of practical

allergology in the present article. Any allergic state needs to be considered through a prism of reaction of

all organism which level is reflection of its reactivity.

1. Pleasants R.A., Walker T.R., Samuelson W.M. Allergic reactions to parenteral

betalactam antibiotics in patients with cystic fibrosis. Chest. 1994. № 106. Р. 1124-1128.

2. Pavlos R., Phillips E.J. Individualization of antiretroviral therapy. Pharmgenomics

Pers Med. 2012. № 5. Р. 1-17.

3. Pichler W.J. Drug Hypersensitivity. Karger, Basel. 2007.

4. Adam J., Pichler W.J., Yerly D. Delayed drug hypersensitivity: models of T-cell

stimulation. Br J ClinPharmacol. 2010. № 71 (5). Р. 701-707.

5. Аsensi V., CollazosJ., Valle-Garay E. Can antiretroviral therapy be tailored to

each human immunodeficiency virus-infected individual? Role of

pharmacogenomics. World J Virol. 2015. № 12. № 4 (3). Р. 169-177.

6. Wah Fung Tse, Weimin Yang, Wenlong HuangA narrative review of costeffectiveness

analysis of people living with HIV treated with HAART: from

interventions to outcomes. Clinicoecon Outcomes Res. 2015. № 7. Р. 431-439.

7. Novikov D.K., Sergeev Y.V., Novikov P.D. Lekarstvennaya allergiia. M. 2001. 312 s.

8. El-Ghaiesh S., Monshi M.M., Whitaker P. et al. Characterization of the antigen

specificity of T-cell clones from piperacillin-hypersensitive patients with cystic

fibrosis. J Pharmacol ExpTher. 2012. № 341. Р. 597-610.

9. Castrejon J.L., Berry N., El-Ghaiesh S. et al. Stimulation of human T cells with

sulfonamides and sulfonamide metabolites. J Allergy ClinImmunol. 2010. № 125.

Р. 411-418.

10. Watkins S., Pichler W.J. Sulfamethoxazole induces a switch mechanism in T

cell receptors containing TCRVbeta20-1, altering pHLA recognition. PLoS One. 2013.

№ 8. 76211 р.

11. Wuillemin N., Adam J., Fontana S. et al. HLA haplotype determines hapten or

p-i T cell reactivity to flucloxacillin. J Immunol. 2013. № 190. Р. 4956-4964.

12. Monshi M.M., Faulkner L., Gibson A. et al. Human leukocyte antigen (HLA)-

B*57:01-restricted activation of drug-specific T cells provides the immunological

basis for flucloxacillin-induced liver injury. Hepatology. 2013. № 57. Р. 727-739.

13. Picard D., Janela B., Descamps V. et al. Drug reaction with eosinophilia and

systemic symptoms (DRESS): a multiorgan antiviral T cell response. SciTransl Med.

2010. № 2. Р. 46-62.

14. Mallal S., Nolan D., Witt C. et al. Association between presence of HLAB*

5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase

inhibitor abacavir. Lancet. 2002. № 359. Р. 727-732.

15. McCormack M., Alfirevic A., Bourgeois S. et al. HLA-A*3101 and

carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011.

№ 364. Р. 1134-1143.

16. Hung S.I., Chung W.H., Liou L.B. et al. HLA-B*5801 allele as a genetic marker

for severe cutaneous adverse reactions caused by allopurinol. ProcNatlAcadSci U S

A. 2005. № 102. Р. 4134-4139.

17. Cargnin S., Jommi C., Canonico P.L. et al. Diagnostic accuracy of HLA-B*57:

01 screening for the prediction of abacavir hypersensitivity and clinical utility of the

test: a meta-analytic review. Pharmacogenomics. 2014. № 15. Р. 963-976.

18. Pirmohamed M., Back D.J. The pharmacogenomics of HIV therapy.

Pharmacogenomics J. 2001. № 1. Р. 243-253.

19. Vitezica Z.G., Milpied B., Lonjou C. et al. HLA-DRB1*01 associated with

cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008.

№ 22. Р. 540-541.

20. Yuan J., Guo S., Hall D. et al. Toxicogenomics of nevirapine-associated

cutaneous and hepatic adverse events among populations of African,Asian, and

European descent. AIDS. 2011. № 25. Р. 1271-1280.

21. Chantarangsu S., Mushiroda T., Mahasirimongkol S. et al. HLA-B*3505

alleleis a strong predictor for nevirapine-induced skin adverse drug reactions inHIVinfected

Thai patients. Pharmacogenet Genomics. 2009. № 19. Р. 139-146.

22. Haas D.W., Bartlett J.A., Andersen J.W. et al. Pharmacogenetics of

nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group

collaboration. Clin Infect Dis. 2006. № 43. Р. 783-786.

23. Martin A.M., Nolan D., James I. et al. Predisposition to nevirapine

hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell

counts. AIDS. 2005. № 19. Р. 97-99.

24. Tassaneeyakul W., Tiamkao S., Jantararoungtong T. et al. Association

between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug

reactions in a Thai population. Epilepsia. 2010. № 51. Р. 926-930.

25. Ding W.Y., Lee C.K., Choon S.E. Cutaneous adverse drug reactions seen in a

tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010. № 49. Р. 834-841.

26. Lonjou C., Borot N., Sekula P. et al. A European study of HLA-B in Stevens-

Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.

Pharmacogenet Genomics. 2008. № 18. Р. 99-107.

27. Ikeda H., Takahashi Y., Yamazaki E. et al. HLA class I markers in Japanese

patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010.

№ 51. Р. 297-300.

28.Genin E., Chen D.P., Hung S.I., Sekula P., Schumacher M., Chang P.Y. etal.

HLAA* 31:01 and different types of carbamazepine-induced severe cutaneous

adverse reactions: an international study and meta-analysis. Pharmacogenomics J.

2014. № 14. Р. 281-288.

29. McCormack M., Alfirevic A., Bourgeois S. et al. HLA-A*3101 and

carbamazepine-induced hypersensitivity reactionsin Europeans. N Engl J Med. 2011.

№ 364. Р. 1134-1143.

30. Ozeki T., Mushiroda T., Yowang A. et al. Genome-wide association study

identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced

cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011.

№ 20. Р. 1034-1041.

31. Lichtenfels M., Farrell J., Ogese M.O. et al. HLA restriction of carbamazepinespecific

T-Cell clones from an HLA-A*31:01-positive hypersensitive patient. Chem

Res Toxicol. 2014. № 27. Р. 175-177.

32. Rodriguesa R. de Oliveira, Germano P. de Carvalhoa, Gomes E.A. de

Arrudacet al. Interleukin-10 gene polymorphism (−1082G/A) and allergy to efavirenz

in patients infected with human immunodeficiency virus. Braz J infect dis. 2014.

№ 1 8(4). Р. 445-448.

33. Jinno H., Tanaka-Kagawa T., Ohno A. et al. Functional characterization of

cytochrome P450 2B6 allelic variants. Drug MetabDispos. 2003. № 31. Р. 398-403.

34. Yuan J., Guo S., Hall D. et al. Toxicogenomics of nevirapineassociatedcutaneous

and hepatic adverse events among populations of African,

Asian, and European descent. AIDS. 2011. № 25. Р. 1271-1280.

35. Sinxadi P.Z., Leger P.D., McIlleron H.M. et al. Pharmacogenetics of plasma

efavirenz exposure in HIV-infected adults and children in South Africa. Br J

ClinPharmacol. 2015. № 80. Р. 146-156.

36. Chung W.H., Chang W.C., Lee Y.S. et al. Genetic variants associated with

phenytoin-related severe cutaneous adverse reactions. JAMA. 2014. № 312. Р. 525-534.

37. Thornhill J., Fidler S., Frater J. Advancing the HIV cure agenda: the next 5

years. Current Opinion in Infectious Diseases. 2015. № 28 (1). Р. 1-9.

38. Di Santo R. Inhibiting the HIV integration process: past, present, and the

future. J Med Chem. 2014. № 57. Р. 539-566.

39. Mammen A.L., Gaudet D., Brisson D. et al. Increased frequency of

DRB1*11:01 in anti-hydroxymethylglutaryl coenzyme A reductase-associated

autoimmune myopathy. Arthritis Care Res (Hoboken). 2012. № 64. Р. 1233-1237.

40. Goldstein J.I., Jarskog L.F., Hilliard C. et al. Clozapine-induced agranulocytosis

is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014. № 5. 4757 р.

41. Yip V.L., Marson A.G., Jorgensen A.L., Pirmohamed M., Alfirevic A. HLA

genotype and carbamazepine-induced cutaneous adverse drug reactions: a

systematic review. ClinPharmacolTher. 2012. № 92. Р. 565-757.

42. Lonjou C., Thomas L., Borot N. et al. A marker for Stevens-Johnson

syndrome.: ethnicity matters. Pharmacogenomics J. 2006. № 6. Р. 265-268.

43. Mallal S., Phillips E., Carosi G. et al. HLAB*5701 screening for hypersensitivity

to abacavir. N Engl J Med. 2008. № 358. Р. 568-579.

44. Daly A.K., Donaldson P.T., Bhatnagar P. et al. HLAB*5701 genotype is a major

determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009.

№ 41. Р. 816-819.

45. Singer J.B., Lewitzky S., Leroy E. et al. A genome wide study identifies HLA

alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010. № 42.

Р. 711-714.

46. Lucena M.I., Molokhia M., Shen Y. et al. Susceptibility to amoxicillinclavulanate-

induced liver injury is influenced by multiple HLA class I and II alleles.

Gastroenterology. 2011. № 141. Р. 338-347.

I.R. Mavlyanov, A.Kh. Ashirmetov, Z.I. Mavlyanov Approach to medical allergy in terms of pathogenesis of different pathological conditions. Medicinskij al'manah 2017; (3): 210–213, http://dx.doi.org/10.21145/2499-9954-2017-3-210-213